MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index

Abstract Background Treatment resistance is a major clinical challenge of diffuse large B-cell lymphoma (DLBCL) where approximately 40% of the patients have refractory disease or relapse. Since DLBCL is characterized by great clinical and molecular heterogeneity, the purpose of the present study was...

Full description

Bibliographic Details
Main Authors: Hanne Due, Rasmus Froberg Brøndum, Ken H. Young, Martin Bøgsted, Karen Dybkær
Format: Article
Language:English
Published: BMC 2020-03-01
Series:BMC Cancer
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12885-020-6643-8